Clinical trial of inhaled ipratropium bromide in the treatment of patients with non-small cell lung cancer combined with chronic obstructive pulmonary disease
10.13699/j.cnki.1001-6821.2024.06.004
- VernacularTitle:吸入式异丙托溴铵治疗非小细胞肺癌合并慢性阻塞性肺疾病患者的临床研究
- Author:
Kuan-Zhe JIN
1
;
Yan-Fei HUANG
;
Xiao-Bo WU
Author Information
1. 南京医科大学附属无锡人民医院胸外科,江苏无锡 214023
- Keywords:
ipratropium bromide;
non-small cell lung cancer;
chronic obstructive pulmonary disease
- From:
The Chinese Journal of Clinical Pharmacology
2024;40(6):802-806
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical effect of inhaled ipratropium bromide in the treatment of patients with non-small cell lung cancer(NSCLC)combined with chronic obstructive pulmonary disease(COPD)and its protective effect on lung function.Methods Clinical data of patients with NSCLC complicated with COPD were retrospectively analyzed.According to the different treatment using cohort methods,the patients were divided into control group and treatment group.After admission,the patients in control group completed the relevant examinations,received conventional anti-infection,oxygen inhalation,asthma,ambroxol injection and other comprehensive treatment,and could be given appropriate mechanical ventilation support according to the development of the patient's condition,and then underwent selective lobectomy.Treatment group inhaled ipratropium bromide treatment:The conventional treatment was the same as control group,combined with atomized ipratropium bromide solution for inhalation 500 μg twice a day,continuous treatment for 1 week,and then selective lobectomy was performed.The clinical efficacy,lung function,inflammatory factor levels and adverse drug reactions were compared between the two groups.Results There were 61 cases in control group and 63 cases in treatment group.After treatment,the total clinical effective rate in treatment group and control group were 76.19％(48 cases/63 cases)and 50.82％(31 cases/61 cases),with significant difference(P＜0.05).After treatment,the forced expiratory volume in the first second(FEV1)of treatment group and control group were(1.89±0.61)and(1.57±0.33)L;the percentage of FEV1 in forced vital capacity(FEV1/FVC)were(73.36±6.58)％and(63.69±6.21)％;peak expiratory flow(PEF)were(3.74±0.81)and(3.24±0.50)L·s-1;interleukin-6(IL-6)were(102.51±7.03)and(133.25±7.75)ng·L-1;hypersensitive C-reactive protein(hs-CRP)were(8.24±2.36)and(18.54±2.31)ng·L-1;tumor necrosis factor-α(TNF-α)were(90.36±5.22)and(114.15±5.13)ng·L-1;white blood cell(WBC)were(91.45±9.31)x 109 and(121.16±9.88)x 109·L-1;the differences were all statistically significant(all P＜0.05).The total incidence of adverse drug reactions was 4.92％(3 cases/61 cases)in control group and 7.94％(5 cases/63 cases)in treatment group,with no statistical significance(P＞0.05).Conclusion Inhaled ipratropium bromide is effective in the treatment of NSCLC complicated with COPD,and has protective effect on lung function and good safety.
